ArticleJournal of the American Heart Association2016
Weight Loss in Obese Patients With Heart Failure.
Article in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Association of weight loss with cardiovascular or all-cause mortality in patients with heart failure: A meta-analysis.International journal of obesity (2005) · 2024Pooled it
- Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Pooled it
- Nutrition in chronic heart failure patients: a systematic review.Heart failure reviews · 2020Pooled it
- Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.European journal of heart failure · 2021Trial
- Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.ESC heart failure · 2018 · on this mapTrial
- Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.Journal of cachexia, sarcopenia and muscle · 2017Trial
- Obesity paradox in heart failure with and without diabetes mellitus: a retrospective cohort study : Obesity paradox and DM in HF.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?European heart journal · 2026Review
- Obesity Is Associated with a Lower Risk of Mortality and Readmission in Heart Failure Patients with Diabetes.Biomedicines · 2025Article
- The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice.Cardiovascular diabetology · 2025Article
- Obesity and heart failure: exploring the cardiometabolic axis.Cardiovascular research · 2025Review
- Clinical Profile and Prognosis of Patients With Acute Decompensated Heart Failure Who Met the Obesity-Related Eligibility for Subcutaneous Semaglutide - Findings From the CURE-HF Registry.Circulation reports · 2025Article
- Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures.Cardiovascular diabetology · 2025Review
- Impact of waitlist weight change on outcomes in heart transplant recipients: a UNOS database analysis.General thoracic and cardiovascular surgery · 2025Article
- Targeting Obesity for Heart Failure.European cardiology · 2025Review
- Leveraging metabolism for better outcomes in heart failure.Cardiovascular research · 2024Review
- Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.Clinical cardiology · 2024Article
- Prognostic influence of weight loss on overweight/obese young heart failure patients.Saudi medical journal · 2024Article
- Association Between Obesity and Lower Short- and Long-Term Mortality in Coronary Care Unit Patients: A Cohort Study of the MIMIC-III Database.Frontiers in endocrinology · 2022Article
- Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn heart failure (HF), weight loss (WL) has been associated with an adverse prognosis whereas obesity has been linked to lower mortality (the obesity paradox). The impact of WL in obese patients with HF is incompletely understood. Our objective was to explore the prevalence of WL and its impact on long-term mortality, with an emphasis on obese patients, in a cohort of patients with chronic HF. METHODS AND
resultsWeight at first visit and the 1-year follow-up and vital status after 3 years were assessed in 1000 consecutive ambulatory, chronic HF patients (72.7% men; mean age 65.8±12.1 years). Significant WL was defined as a loss of ≥5% weight between baseline and 1 year. Obesity was defined as body mass index ≥30 kg/m(2) (N=272). Of the 1000 patients included, 170 experienced significant WL during the first year of follow-up. Mortality was significantly higher in patients with significant WL (27.6% versus 15.3%, P<0.001). In univariable Cox regression analysis, patients with significant WL had 2-fold higher mortality (hazard ratio 1.95 [95% CI 1.39-2.72], P<0.001). In multivariable analysis, adjusting for age, sex, body mass index, New York Heart Association functional class, left ventricular ejection fraction, HF duration, ischemic etiology, diabetes, and treatment, significant WL remained independently associated with higher mortality (hazard ratio 1.89 [95% CI 1.32-2.68], P<0.001). Among obese patients with HF, significant WL was associated with an even more ominous prognosis (adjusted hazard ratio for death of 2.38 [95% CI 1.31-4.32], P=0.004) than that observed in nonobese patients (adjusted hazard ratio 1.83 [95% CI 1.16-2.89], P=0.01).
conclusionsWeight loss ≥5% in patients with chronic HF was associated with high long-term mortality, particularly among obese patients with HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.